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physical deterioration and 
adaptive recovery in physically 
inactive breast cancer patients 
during adjuvant chemotherapy: a 
randomised controlled trial
tom Møller  1,4 ✉, Christina Andersen1, Christian Lillelund1, Kira Bloomquist1, 
Karl Bang christensen4, Bent ejlertsen2, Malgorzata tuxen2, Peter oturai5, Ulla Breitenstein2, 
cecilie Kolind3, Pernille travis3, Tina Bjerg2, Mikael Rørth2 & Lis Adamsen1,4
Cardiorespiratory fitness is an independent risk factor for cardiovascular disease and shortened 
life expectancy in breast cancer survivors. This randomised controlled trial (n = 153) was designed 
for patients with a physically inactive lifestyle prediagnosis and concurrently referred to adjuvant 
chemotherapy. We compared two 12-week exercise interventions aimed at physiological and patient-
reported outcomes (cardiorespiratory fitness, muscle strength, metabolic markers, physical activity, 
pain, fatigue), including a 39-week follow-up. A supervised hospital-based moderate to high intensity 
group exercise intervention was compared to an instructed home-based individual pedometer 
intervention. The two 12-week interventions included oncologists’ recommendations and systematic 
health counselling. Outcomes were measured at baseline and week 6, 12 and 39. Primary outcome 
cardiorespiratory fitness declined significantly during chemotherapy and was restored in both 
interventions at follow-up. The interventions effectively engaged breast cancer patients in sustaining 
physical activities during and following adjuvant treatment. A composite metabolic score improved 
significantly. Positive cardiorespiratory fitness responders had improved clinical effects on fatigue, 
pain and dyspnoea versus negative responders. We conclude that a loss of cardiorespiratory fitness 
among physically inactive breast cancer patients may be restored by early initiated interventions and 
by adapting to physical activity recommendations, leading to a decreased cardiovascular risk profile in 
breast cancer survivors.
Physical inactivity and sedentary behaviour represent a challenge for global health due to a significant risk 
of pre-mature death from chronic diseases such as cardiovascular diseases, diabetes and cancer1,2. In breast 
cancer (BC), physical inactivity and obesity has consistently been associated with an increased risk of recur-
rence3,4, though physiological, biological and molecular pathways are partly known5–8. Low cardiorespiratory 
fitness (CRF) increases risk for coronary heart disease and affects survival in BC survivors9, similar to asymp-
tomatic women10, low-risk adults11 and high-risk sedentary populations12,13. Compared with healthy sedentary 
Americans, a relative 25% decline in CRF has been shown to be a primary recurring effect in the BC trajectory14, 
a finding confirmed in a German cross-sectional study15. The causal mechanisms involved in this decline in CRF 
in patients with BC may be related to a cascade of factors in the oxygen delivery system15–17. These factors may 
1The University Hospitals Centre for Health Research (UCSF), Copenhagen University Hospital, Rigshospitalet, 
Department, 9701, Copenhagen, Denmark. 2Copenhagen University Hospital, Rigshospitalet, Department of 
Oncology, 7301, Copenhagen, Denmark. 3Copenhagen University Hospital, Herlev Hospital, Department of 
Oncology, Herlev, Denmark. 4University of Copenhagen, Faculty of Health and Medical Sciences, Department of 
Public Health, Copenhagen, Denmark. 5Copenhagen University Hospital, Rigshospitalet, Department of Clinical 
Physiology, Nuclear Medicine and PET, Copenhagen, Denmark. ✉e-mail: tommoel@icloud.com
open
2Scientific RepoRtS |         (2020) 10:9710  | https://doi.org/10.1038/s41598-020-66513-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
include direct chemotherapy toxic impairment on the left ventricular function and endothelial damage, in com-
bination lifestyle factors with a negative effect, such as physical inactivity and weight gain17,18.
Various studies point out the importance of having built-in, regular physical activity (PA) in multimodal 
cancer supportive care and rehabilitation19–21. There appears to be a potential health gain related to moderate and 
high intensity PA, with the highest effect on CRF and mortality observed in individuals performing high intensity 
exercise compared to controls or sedentary populations22,23. A recent systematic review on cancer survivors24, 
e.g. sedentary BC survivors25, found that walking was the strongest PA modality preference. Nonetheless, less 
attention has been paid to recruiting physically inactive cancer patients in exercise programmes26. It remains 
unclear what the optimal setting, timing during cancer trajectory, dosage and combination of exercise and 
health-promoting components that best facilitate patient adherence and symptom management to support phys-
iological improvements and sustainable lifestyle changes in a physically inactive BC population27. Prevention of 
a decline in CRF may have a salutogenic medical effect that necessitates the integration of lifestyle modifications 
in BC oncology28–30 that specifically support behavioural aspects when recommended PA guidelines are not met.
However, recent randomised controlled trials (RCTs) among patients with BC have raised concerns about 
the potential interventional effect on CRF during adjuvant chemotherapy and at follow-up23,31,32. This concern 
appears to derive from a shift in chemotherapy regimens incorporating taxane-based chemotherapy, implicat-
ing an altered patient symptom profile33,34. In the randomised feasibility study preceding the present RCT, we 
used Danish national PA guidelines as the initial screening inclusion criteria35. This simplified two-item tool was 
able to detect physically inactive BC patients at onset of adjuvant chemotherapy with a high correlation of low 
VO2peak at baseline compared with the Scandinavian background population27. Qualitative in-depth studies 
indicate that a recommendation from clinicians to exercise at the specific timepoint around chemotherapy onset 
is ideal for recruiting subjects and initiating PA36. Moreover, we proposed an overall framework for transforming 
behavioural change towards re-thinking PA into post-cancer life priorities in an at-risk, physically inactive BC 
population36.
The present RCT aimed to compare the effects of two 12-week exercise interventions on physiological out-
comes (e.g. CRF, muscle strength, body composition, blood cholesterol and insulin) and patient-reported out-
comes (e.g. PA, pain, fatigue, dyspnoea and anxiety), including a 39-week follow-up. The population comprised 
screened, physically inactive BC patients at onset of adjuvant chemotherapy that included sequential anthracy-
cline and cyclophosphamide with docetaxel or paclitaxel-based regimens.
patients and methods
Research design and study population. This study was designed as an assessor single-blinded two-cen-
tre RCT comparing a structured 12-week supervised hospital-based group exercise intervention (Group 1 (Gr. 1)) 
versus a 12-week instructed home-based individual pedometer intervention (Group 2 (Gr. 2)) during adjuvant 
chemotherapy among confirmed physically inactive patients with BC. Both interventions were combined with 
health and symptom guidance given by a clinical nurse specialist. The primary outcome of interest was CRF 
(CRF/VO2peak). The RCT was analysed and published according to Consolidated Standards of Reporting Trials 
(CONSORT) guidelines37.
Patients who had symptomatic heart disease, bone metastasis, received neo-adjuvant chemotherapy, suffered 
from psychotic conditions or did not understand Danish were excluded. Patients who met the national criteria for 
leisure time PA were not eligible for the study27,35,38.
Setting. This study was conducted at the Departments of Oncology, Copenhagen University Hospital, 
Rigshospitalet and Herlev Hospital at the Centre for Integrated Rehabilitation of Cancer Patients (CIRE), 
Copenhagen, Denmark and was established and supported by the Danish Cancer Society and the Novo Nordic 
Foundation. CIRE adheres to three key intervention principles: (1) early initiation of an intervention during can-
cer treatment; (2) exercise/physical activity and (3) patient activation (EEX-ACT)39.
Approvals. Ethics approval and consent to participate. All patients provided informed written con-
sent and all methods were performed in accordance with the relevant guidelines and regulations. This study 
was approved by the Scientific Committee of the Capital Region of Denmark (file no. H3-2013-155), and the 
Danish Data Protection Agency (file no. 2011-41-6349). Trial registration: Current Controlled Trials 13/03/2014 
ISRCTN13816000.
Procedure. Eligible BC patients were identified with a pre-screening instrument based on PA guidelines from 
the Danish Health and Medicines Authority (>150 minutes of regular and moderate recreational PA and at least 
2 × 20 min of strenuous exercise per week)35. The oncologists or primary nurse present during the patients’ adju-
vant chemotherapy provided the initial screening assessment of these two PA parameters. A clinical nurse spe-
cialist on the exercise team subsequently gave in-depth information to physically inactive BC patients about the 
study’s rationale, tests and intervention. Baseline testing was planned between the first and second cycle of epi-
rubicin and cyclophosphamide (see Fig. 1). Patients were stratified by age (<48>) and hospital setting and then 
randomly assigned 1:1, either to Gr. 1 or Gr. 2, by the Copenhagen Trial Unit. Informed consent was obtained 
from every participant included in the study.
Interventions. The protocol for this study described and compared the two pragmatic interventions in more 
detail38, while the feasibility study investigated the validity of the PA screening tool related to the primary out-
come (CRF), patient acceptance, interventional safety, adherence and programme feasibility27,36.
Supervised exercise intervention. 12-week supervised hospital-based group exercise intervention and health 
counselling and symptom guidance.
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Patients were offered a 12-week supervised exercise programme (PART1: six weeks, 9 h/week and PART2: 
six weeks, 6 h/week) in groups of 10–14 patients supervised by an exercise physiologist/physical therapist and a 
clinical nurse specialist. PART1 included three training sessions per week and one restorative session comprising 
high-low-intensity components (cardiorespiratory training on stationary bikes, resistance training, relaxation 
training and massage). PART2 comprised the sports floorball games, dance and circuit training. The total training 
volume in PART1 and PART2 corresponded to approximately a 40-metabolic equivalent of task hours per week19. 
Pre-exercise safety screening took place before each session and involved moderate-to-high-intensity physical 
training components19,38.
Instructed pedometer intervention. Individual 12-week instructed home-based pedometer intervention and 
health counselling and symptom guidance.
The instructed pedometer intervention was a 12-week individually organised programme designed to pro-
gressively support increased PA and was predominantly provided by a clinical nurse specialist in cancer and 
exercise. Patients were encouraged to enhance their PA levels and to avoid physical inactivity by integrating exer-
cise into activities of daily living. The initial explicit goal was to achieve a low to moderate recreational PA level 
of 30 min/day (aerobic walking) and, stepwise, to achieve 7,500 steps/day five times per week, with the ultimate 
goal of incorporating 150 minutes of moderate-to-vigorous PA per week40,41. The Omron Walking Style Pro 2.0 
Pedometer made it possible to visually portray the patients’ exercise achievements on a daily, weekly and monthly 
basis at a scheduled instruction and evaluation meeting baseline at weeks 2, 4, 6, 9 and 12. Pedometer data were 
transferred electronically to investigators.
Health counselling and symptom guidance. Patients in both interventions received individual test feedback and 
health counselling and symptom guidance at baseline and at weeks 6, 12 and 39 to help counteract barriers and to 
support individual motivational aspects to initiate and prioritise leisure time PA27,38. The theoretical framework 
for initiating and adopting behavioural change at onset and during adjuvant chemotherapy focused on recognis-
ing pre-exercise history, individual goal planning, family resources and the immediate pitfalls during anticancer 
treatment as crucial determinants for the individual to rethink regular exercise as pivotal for their health and 
post-cancer life priorities36.
Assessments, outcomes and data protection. Patient assessment of primary outcome, CRF/VO2peak, 
and secondary outcomes was conducted at time of inclusion, baseline (TO); week 6, midway (T1); week 12, 
completed (T2); and week 39, follow-up (T3) (six months after intervention and chemotherapy and irradiation 
completed) (Table 1). Assessments were blinded to test personnel (affiliated health professionals trained by an 
exercise physiologist). Fasting, whole-body dual-energy X-ray absorptiometry was performed by medical techni-
cians who were not involved in group allocation or interventional activities at Copenhagen University Hospital, 
Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET. Figure 1 provides a global study 
overview.
All outcomes were entered into a secure database with tracking hosted by the Copenhagen Trial Unit at 
Copenhagen University Hospital. Data access for study researchers was provided when the last sequentially num-
bered patient had completed the T2 assessment (Table 1).
Power calculation and statistics. Based on the a priori assumption that the supervised exercise inter-
vention will be more effective in maintaining or increasing aerobic capacity (VO2peak), sample size was based 
on an expected mean difference between groups of VO2peak 180 ml/min and with a standard deviation (SD) of 
2419,23,27. With a power of 0.9, a dropout rate of 25% and assuming that the population would comprise 70% true 
non-training, physically inactive patients (VO2peak measure compared against the background population)48, the 
final sample included n = 77 in each study arm, yielding 154 patients.
The principal analyses of primary and secondary outcomes employed the intention-to-treat approach by 
including all available data. Data were reported as means and SDs. Change scores and differences between change 
scores were derived from the linear mixed model along with corresponding 95% confidence intervals using the 
delta method. No attempts at imputation beyond those implicit in linear mixed models were implemented for 
Figure 1. Global study overview during chemotherapy.
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subjects with missing follow-up data, but pattern mixture models were performed for the primary outcome drop-
out analyses49. Baseline demographic characteristics were provided with 95% confidence intervals.
Results
Patients. A total of 711 patients were screened for eligibility, 60% of whom were considered physically inac-
tive prior to their diagnosis, while 40% met national PA recommendations. Study recruiters failed to establish 
contact with 53 patients (13.5%). With 185 patients declining to participate, the study acceptance rate was 45%. 
The study attrition rate was 15% for each study group at T2. At T3 it was 17% for Gr. 1 and 24% for Gr. 2 (Fig. 2). 
Test adherence at week 12 was 85% in both the supervised exercise and the instructed pedometer interventions. 
Programme adherence measured for 12-week completers was 1617/2304 or 70.2% for supervised exercise partic-
ipation and 378/396 or 95.5% for PA pedometer instruction meetings.
No adverse events prompting medical attention occurred during the supervised exercise sessions. Three minor 
training-related injuries occurred (pulled muscle, sprained foot, back problem). Two patients experienced a lower 
dyspnoea threshold during moderate intensity training with no further action taken. Another two minor adverse 
events (temporary swelling and foot pain) related to the instructed pedometer intervention were reported.
The stratified randomisation procedure balanced baseline characteristics across groups (Table 2). Five patients 
(3%) reported doing some moderate to strenuous PA, while approximately one-third (36%) reported doing low 
to moderately active PA > 150 minutes per week. At baseline, 90% had a VO2peak lower than the age-matched 
background population of Scandinavian women. Participants received four courses of chemotherapy during the 
intervention period consisting of one or two courses of epirubicin and cyclophosphamide followed by two or 
three courses of docetaxel-based chemotherapy. For nineteen participants, one series of docetaxel was replaced 
with three series of paclitaxel as standard treatment, equally distributed between groups.
Primary outcome. The incremental test on the cycle ergometer with direct measures of respiratory gases was 
performed with a high reliability (Fig. 3). The primary outcome, VO2peak, decreased significantly in both study 
groups (Gr. 1: 6.2%, Gr. 2: 9.1%) from baseline to week 12 (T2) without any between-group difference. Both study 
groups restored VO2peak from week 12 to week 39 (p < 0.0001) with no significant between-group differences 
observed (Fig. 3, Panel A). There was a higher attrition rate in Gr. 2 among 12 patients with lower mean VO2peak 
baseline values, which is in accordance with the power calculation and exceeded the minimal clinical relevance of 
180 ml/min at week 12. However, a dropout analysis at week 12 showed no differences in socio-demographics or 
ASSESSMENT INSTRUMENT/METHOD TIMEPOINT
Primary outcome
Cardiorespiratory fitness/oxygen uptake
Maximal oxygen uptake (VO2peak); incremental test on cycle 
ergometer (Monark Ergomedic 839E) with direct measures of 
respiratory gases27,38
Assessment of physical exertion on physiological tests (1.10 
and >1.15) and the Borg Scale42
T0, T1, T2, T3
T0, T1, T2, T3
Secondary physiological outcomes
Body composition (fat mass, lean mass, 
bone density)
Fasting whole-body DXA scan (fat percent, visceral fat, lean 
mass, android/gynoid ratio, bone mass density43,44 T0, T2, T3
Muscle strength
Isokinetic maximum knee extension strength (600/sec.)
(Contrex MJ Isokinetic Dynamometer CMV AG, Switzerland)
Maximum load (one repetition maximum = 1RM) measured 
at knee extension, leg press and lateral pull
(Technogym (Gambettola, Italy)
T0, T1, T2, T3
T0, T1, T2, T3
Biomarkers Lipids, cholesterols, blood glucose, insulin14 T0, T2, T3
Metabolic syndrome profile Composite score: cholesterol, triglyceride, blood glucose, blood pressure, android/gynoid (AG) ratio45
Blood pressure Test, A&D Medical UA-852 Digital Blood Pressure Monitor T0, T1, T2, T3
Haemoglobin Test T0, T1, T2, T3
Physical activity (objective) Pedometer in home-based exercise programme, Omron Walking Style Pro 2.027
T0 to T2 continuous
(solely pedometer group)
Pulse Pulse sensor during supervised exercise intervention, Polar Team System 2, Polar, Finland
T0 to T2 continuous (supervised 
exercise group only)
Psychometric measures
Health-related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire46 T0, T1, T2, T3
Anxiety and depression Hospital Anxiety and Depression Scale47 T0, T1, T2, T3
Physical activity (subjective), labour 
market, lifestyle factors (smoking, 
alcohol, diet)
Self-developed questionnaire with guideline-based physical 
activity scale35 T0, T1, T2, T3
Clinical characteristics and treatment Medical records Continuous
Diagnosis, stage, anti-cancer treatment
Table 1. Outcome assessments, instruments and timepoints. Abbreviations: TO = baseline; T1 = week 6, 
midway; T2 = week 12, completed; T3 = week 39, follow-up; DXA = dual-energy X-ray absorptiometry; 
1RM = one repetition maximum.
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treatment characteristics among completers and non-completers. At week 39 the difference in baseline VO2peak 
between completers and non-completers did not exceed the minimal clinically important threshold.
The incremental peak power output (IPPO) differed significantly between study groups, favouring the super-
vised exercise intervention but did not remain significant at T3 (Fig. 3, Panel B). Similar to VO2peak measures, 
the mean baseline IPPO was lower among patients with no follow-up assessments.
Secondary outcomes. Self-reported physical activity level. Figure 4 Panels A and B presents the 
self-reported prevalence in PA in accordance with Danish national PA guidelines. Both study groups showed a 
highly significant increase in moderate PA from baseline (T0) to intervention completion (T2) that remained at 
Figure 2. Consort flow chart: recruitment and completion.
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the week-39 follow-up (T3). The incorporation of high-intensity PA components was increased significantly in 
both study groups; however, there was a significant difference in favour of the supervised exercise intervention 
compared to the instructed pedometer intervention during the 12-week period and at T3 (p = 0.0408). At T3, 
more than 50% met the national PA guidelines for adults.
Muscle strength and isokinetic measures. The supervised exercise intervention showed within-group increases 
in strength using the one repetition maximum test (knee extension, lateral pull and leg press), with significant 
between-group differences visible at intervention completion (T2) and sustained at follow-up (T3). The isokinetic 
measures significantly favoured the supervised exercise intervention when it concluded (T2), but there was no 
between-group significance at week 39 (T3), where baseline isokinetic measures were restored (Table 3).
Body composition. Body weight remained stable during the intervention period, with a significant decrease at 
T3 in the supervised exercise intervention, though there were no between-group differences. Lean body mass 
increased significantly from T0-T2 and dropped to baseline levels at T3. Fat mass decreased in the supervised 
exercise intervention at follow-up (T3) with no difference observed between groups. In both groups there was 
a significant loss of bone mass content from T0 to T3, while bone mass density had increased significantly in 
Total (N = 
153)
Supervised hospital- based 
exercise intervention (n=75)
Instructed pedometer 
intervention (n=78)
diff(95% confidence 
interval)
Age, mean ± SD (y) 51.7 ± 9.4 51.5 ± 9.6 52.0 ± 9.3 −0.5 (−3.5 to 2.5)
BMI, mean ± SD (kg/m2) 26.1 ± 5.1 26.2 ± 5.3 26.0 ± 4.9 0.2 (−1.4 to 1.9)
Marital status n (%)
Single/divorced/widowed 50 (33) 26 (35) 24 (31) 3 (−12 to 18.1)
Married/living together 103 (67) 49 (65) 54 (69) −4 (−18.1 to 12)
Education n (%)
Lower 12 (7.9) 7 (9.3) 6 (7.7) 1.6 (−8.1 to 9.2)
Secondary 48 (31.8) 25 (33.3) 24 (30.8) 2.5 (−12.8 to 17)
Advanced 91 (60.3) 43 (58.9) 48 (61.5) −2.6 (−18.3 to 13)
Smoking n (%)
Never/ex-smoker* 138 (90.8) 68 (90.7) 70 (89.7) 1.0 (−9.4 to 9)
Current 15 (9.8) 7 (9.3) 8 (10.3) −1.0 (−9 to 9.4)
Alcohol
Intake per week, median 2 (0 to 5.5) 2 (1 to 6.5) 2 (0 to 5) 0 (0 to 1)
Physical activity. Prediagnosis No. (%)
Light-moderate PA <150 min/week 99 (65) 44 (59) 55 (71) −12 (−27 to 3.2)
Light-moderate PA >150 min/week 54 (35) 31 (41) 23 (29) 11.8 (−3.2 to 27)
Strenuous activity <2 × 20 min/week 148 (97) 73 (97) 75 (96) 1.2 (−4.4 to 6.8)
Strenuous activity >2 × 20 min/week 5 (3) 2 (3) 3 (4) −1.2 (−6.8 to 4.4)
Cancer stage, n (%)
Stage 1 56 (36.6) 31 (41.3) 25 (31.1) 9.3 (−5.9 to 24.5)
Stage 2 81 (52.9) 36 (48.0) 45 (57.7) −9.7 (−25.4 to 6.1)
Stage 3 16 (10.5) 8 (10.7) 8 (10.3) 0.4 (−9.3 to 10.1)
Breast surgery, n (%)
Lumpectomy 90 (58.8) 47 (62.7) 43 (55.1) 7.5 (−8 to 23.1)
Mastectomy 56 (36.6) 26 (34.7) 30 (38.5) −3.8 (−19 to 11.5)
Mastectomy plus expander 7 (4.6) 2 (2.7) 5 (6.4) −3.7 (−10.3 to 2.8)
Chemotherapy, n (%)
Q3Wy CE × 3 -> Q3W docetaxel × 3 130 (85.0) 66 (88.0) 64 (82.1) 5.9 (−5.3 to 17.2)
Q3W CE × 3 -> weekly paclitaxel × 9 19 (12.4) 8 (10.7) 11 (14.1) −3.4 (−13.9 to 7)
Other 4 (2.6) 1 (1.3) 3 (3.9) −2.5 (−7.5 to 2.5)
Pegfilgrastim n (%) 114 (75) 56 (75) 58 (74)
Radiotherapy, n (%) 121 (79.1) 58 (77.3) 63 (80.8) −3.4 (−16.3 to 9.5)
Herceptin, n (%) 44 (28.8) 22 (29.3) 22 (28.2) 1.1 (−13.2 to 15.5)
Endocrine treatment, n (%) 118 (77.1) 59 (78.7) 59 (75.6) 3.0 (−10.3 to 16.3)
Tamoxifen 62 (41) 33 (44) 29 (37) —
Letrozole 44 (29) 21 (28) 23 (29) —
Other 12 (8) 5 (7) 7 (9) —
Table 2. Baseline characteristics. Abbreviations: diff=difference; BMI = body mass index; *cessation>1 year; 
Q3W = every three weeks; CE = cyclophosphamide and epirubicin.
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both study groups at T3. T-scores decreased significantly from T0 to T3 without reaching levels for osteopenia50. 
(Table 4).
Blood markers. Blood markers showed no between-group difference (P-glucose, P-insulin, P-cholesterol, 
high-density lipoprotein cholesterol, high-density lipoprotein cholesterol), except for P-triglyceride, which was 
significantly lowered in the pedometer group at week 39 (T3). Total cholesterol generally remained elevated 
(5.3–5.4 SD 1.1) and unchanged. Blood glucose and cholesterol remained relatively stable, though a slightly sig-
nificant increase was visible for high-density lipoprotein in Gr. 2 at follow-up (T3). For a full analysis see online 
Supplemental Material.
A composite metabolic syndrome score of five biological and physiological variables was calculated for each 
group (Fig. 5). Three (or more) out of five risk variables were classified as a case. The findings revealed a signifi-
cant improvement in the metabolic risk profile from baseline to week 39 for both groups (Gr. 1, p = 0.0493; Gr. 
2, p = 0.0156).
Selected patient-reported outcomes. There were no significant between-group changes on the 
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) 
or the Hospital Anxiety Depression Scale. Fatigue, pain, dyspnoea and insomnia worsened significantly during 
Figure 3. Primary outcome.
Figure 4. Percentage doing moderate and high intensity physical activity.
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chemotherapy without between-group differences and was restored significantly to baseline levels at follow-up. 
Anxiety remained relatively stable during the study period, whereas depression increased from baseline to T2 and 
was significantly below the baseline values at T3 (Table 5).
Figure 6 provides an overview and comparison of effect sizes (cohens d) between study groups at T2 assess-
ment for the primary outcome, VO2peak, and secondary measures. In general, effect sizes reflect benefits favour-
ing the supervised exercise intervention in physiological outcomes and physical functioning, whereas effects on 
patient-reported measures were heterogenous between groups.
Explorative analysis of VO2 peak. By merging VO2peak data across study groups, we dichotomised VO2peak 
into positive responders/unchanged (n = 41, 32%) and negative responders >2% (n = 87, 68%) from baseline to 
week 12. Positive/unchanged responders had improved clinical effects on EORTC QLQ scores versus negative 
responders: fatigue (51.3 SD 28 vs. 60.0 SD 24.6); pain (26.9 SD 25.8 vs. 41.7 SD 30.7); and dyspnoea (17.9 SD 26.3 
vs. 30.7 SD 28.9). There were no significant differences in baseline scores or at follow-up (T3) between responders 
and decliners.
Correlation analyses between changes in (delta), physiological outcomes (VO2peak, muscle strength) and 
(delta) selected patient-reported outcome scales (fatigue, pain, dyspnoea) at week 12 revealed a very weak corre-
lation between strength and delta fatigue, pain and dyspnoea, whereas VO2peak demonstrated a significant weak 
correlation on EORTC QLQ fatigue, pain and dyspnoea. Parametric testing indicated that an improvement on 
VO2peak with 100 ml/min would decrease fatigue by 4 points, whereas, e.g. a gain in lean body mass by 0.5 kg 
would result in a decrease in fatigue by 1.4 points. Delta VO2peak (100 ml) or delta leg press (10 kg) improvements 
were significantly correlated with reduced pain scores (average 3 EORTC QLQ points). (Table 6).
Variable
Allocation T0 (n = 153) T1 (n = 124) T2 (n = 127) T3 (n = 112)
(95% CI) p
Between group
pgroup Mean (SD) Mean (SD) Mean (SD) Mean (SD) diff kg (95% CI)
1RM knee extension (kg)
1 39 (10) 47 (10) 8 (6 to 10) <0.0001 8 (5 to 10) *<0.0001
2 41 (12) 41 (12) 0 (−2 to 2) 0.8138 —
1 39 (10) 49 (10) 10 (7 to 12) <0.0001 8 (4 to 11) *<0.0001
2 42 (13) 43 (13) 2 (−1 to 4) 0.1493 —
1 39 (9) 46 (10) 7 (4 to 9) <0.0001 6 (2 to 9) *0.0022
2 41 (12) 43 (12) 1 (−1 to 4) 0.3197 —
1RM lateral pull (kg)
1 29 (7) 33 (7) 4 (2 to 6) <0.0001 3 (1 to 5) *0.0173
2 30 (8) 32 (7) 1 (−1 to 3) 0.168 —
1 30 (7) 36 (7) 6 (4 to 8) <0.0001 4 (1 to 7) *0.0050
2 30 (8) 32 (7) 2 (0 to 4) 0.0525 —
1 29 (7) 33 (6) 4 (2 to 6) 0.0001 3 (0 to 6) *0.0287
2 30 (7) 31 (7) 1 (−1 to 3) 0.4116 —
1RM leg press (kg)
1 84 (27) 106 (33) 21 (16 to 26) <0.0001 20 (13 to 27) *<0.0001
2 85 (36) 86 (38) 1 (−4 to 6) 0.6769 —
1 84 (27) 108 (36) 24 (18 to 29) <0.0001 22 (14 to 29) *<0.0001
2 86 (36) 87 (38) 2 (−3 to 7) 0.4468 —
1 82 (26) 103 (37) 21 (16 to 27) <0.0001 18 (10 to 26) *<0.0001
2 84 (35) 87 (36) 3 (−3 to 8) 0.2951 —
Contrex Peak right
1 117 (23) 118 (23) 1 (−2 to 4) 0.4679 4 (0 to 8) 0.0518
2 119 (29) 116 (29) −3 (−6 to 0) 0.0447
1 118 (23) 118 (22) 1 (−3 to 4) 0.6659 6 (1 to 11) *0.0126
2 120 (29) 114 (27) −5 (−9 to −2) 0.0019
1 116 (23) 115 (23) −1 (−5 to 3) 0.5158 2 (−3 to 8) 0.422
2 120 (30) 116 (29) −4 (−8 to 0) 0.0752
Contrex Peak left
1 116 (23) 120 (21) 4 (1 to 6) 0.0191 5 (1 to 9) *0.0246
2 119 (29) 117 (28) −1 (−4 to 2) 0.3916
1 116 (24) 118 (24) 2 (−2 to 5) 0.2956 6 (1 to 11) *0.0269
2 119 (30) 115 (30) −4 (−7 to 0) 0.0354 —
1 116 (22) 116 (22) 1 (−4 to 5) 0.7467 4 (−2 to 11) 0.1879
2 121 (30) 116 (28) −4 (−8 to 1) 0.1245 —
Table 3. Strength (1RM) and isokinetic measures (Contrex). Abbreviations: diff=difference; TO = baseline; 
T1 = week 6, midway; T2 = week 12, completed; T3 = week 39, follow-up; n = maximum n for patients at 
baseline test and associated follow-up test; *=between-group significance p < 0.05; SD = standard deviation; 
CI = confidence interval; diff = difference; 1RM = one repetition maximum test; allocation group 1 = 
supervised exercise intervention; allocation group 2 = instructed pedometer intervention.
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Discussion
Contrary to our a priori hypothesis, we observed no in-between group difference on the primary outcome, 
VO2peak (CRF), in supervised hospital-based moderate to high intensity group exercise intervention versus an 
instructed home-based individual pedometer programme. A decline in VO2peak was observed in both groups 
after onset of chemotherapy, and VO2peak was fully restored at week 39. Our results disprove a lasting CRF loss 
due to chemotherapy, as previously suggested14–16. Other intervention RCTs have found an even further reduc-
tion in CRF during adjuvant taxane-based chemotherapy, though some natural improvement in CRF may occur 
in RCT controls23,31,32. In observational studies CRF has been inversely associated with mortality in clinical and 
population cohorts11,51–54. Furthermore, physically inactive survivors of BC are at increased risk of post-treatment 
cardiovascular disease and cancer recurrence29,55,56, and only few powered intervention RCTs have explored the 
adaptationally positive impact of regular PA on disease-free survival and all-cause mortality57. There is also a 
lack of studies explicitly recruiting cancer patients to PA interventions during treatment who were physically 
Variable Group
T0: Mean (SD) (n 
= 153)
T2: Mean (SD) (n 
= 128)
T3: Mean (SD) (n 
= 115) Delta (95% CI) p diff (95% CI) p
Weight (kg)
1 74.7 (14.3) 74.6 (13.9) −0.1 (−1 to 0.8) 0.8320 −0.4 0.5866
2 73 (13.7) 73.3 (14) 0.3 (−0.7 to 1.2) 0.576 (−1.7 to 1.0)
1 75.1 (14.7) 74 (13.6) −1.1 (−2.1 to −0.2) 0.0215 −0.6 0.4068
2 72.7 (13) 72.1 (13.2) −0.6 (−1.5 to 0.4) 0.2594 (−2.0 to 0.8)
Fat mass (g)
1 29342 (10039) 28169 (9815) −1152 (−2307 to 3) 0.0507 −834 (−2457 to 788) 0.3120
2 28060 (9358) 27767 (9601) −318 (−1457 to 822) 0.5834
1 29859 (10179) 30269 (11690) 456 (−736 to 1648) 0.4522 795 (−894 to 2484) 0.3548
2 27678 (8754) 27353 (8707) −339 (−1536 to 858) 0.5770
Bone mass 
content (g)
1 2497.2 (346.2) 2492.5 (350.8) −4.2 (−22.8 to 14.5) 0.6608 −13.3 0.3191
2 2407.9 (337.9) 2417.2 (333.2) 9.1 (−9.3 to 27.5) 0.3299 (−39.4 to 12.9)
1 2482.7 (346.4) 2433.1 (335.5) −48.4 (−67.6 to −29.1) <0.0001 −12.9 0.3513
2 2412.3 (348.6) 2376.5 (344.6) −35.4 (−54.8 to −16.1) 0.0004 (−40.2 to 14.3)
Lean body 
mass (g)
1 42842 (5218) 43916 (5304) 1048 (592 to 1505) <0.0001 486 (−156 to 1127) 0.1372
2 42545 (5465) 43102 (5710) 563 (112 to 1013) 0.0146
1 42733 (5380) 42722 (5057) −78 (−549 to 394) 0.7456 82 (−586 to 750) 0.8086
2 42556 (5402) 42442 (5398) −160 (−633 to 314) 0.5064
Bone mineral 
density
1 1.20 (0.12) 1.23 (0.23) 0.03 (0.00 to 0.07) 0.0696 0.02 (−0.03 to 0.07) 0.459
2 1.16 (0.19) 1.18 (0.12) 0.01 (−0.02 to 0.05) 0.4283
1 1.19 (0.11) 1.18 (0.11) −0.01 (−0.04 to 0.03) 0.6288 0.00 (−0.05 to 0.05) 0.9815
2 1.16 (0.19) 1.15 (0.12) −0.01 (−0.04 to 0.03) 0.6066
T-score (SD)
1 1.21 (1.19) 1.19 (1.18) −0.02 (−0.08 to 0.05) 0.6585 −0.04 (−0.13 to 0.06) 0.4343
2 0.93 (1.24) 0.95 (1.18) 0.02 (−0.04 to 0.09) 0.5056
1 1.14 (1.15) 0.99 (1.10) −0.15 (−0.22 to −0.08) <0.0001 0.03 (−0.07 to 0.13) 0.5395
2 0.86 (1.24) 0.69 (1.21) −0.18 (−0.25 to −0.11) <0.0001
Table 4. DXA scan body mass measures. Abbreviations: TO = baseline; T1 = week 6, midway; T2 = week 12, 
completed; T3 = week 39, follow-up; DXA = dual-energy X-ray absorptiometry; n = maximum n for patients 
at baseline test and associated follow-up test; 1 = group 1 supervised exercise intervention; 2 = group 2 
pedometer exercise intervention; SD = standard deviation; CI = confidence interval.
Figure 5. Metabolic syndrome.
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inactive/sedentary prediagnosis26,58. Consequently, we cannot clarify whether results from the vast majority of 
studies and meta-analyses are derived from selective populations of cancer patients with a predominant prefer-
ence for PA21,59–61, or whether recruitment, intervention activities and outcome expectations can be transferred 
to an at-risk subgroup with less PA experience and beyond the context of a trial environment. Patient-reported 
PA levels, a secondary outcome, supported our physiological findings, and we suggest that a loss in CRF can be 
restored by sustainable adaption to national PA guidelines across intervention approaches and among physically 
inactive survivors with BC.
The two-item screening tool based on national PA guidelines identified 60% as being physically inactive 
against 40% meeting PA guidelines at chemotherapy onset. The study acceptance rate of 45% is comparable to 
exercise RCTs that do not exclusively recruit screened, physically inactive patients with BC referred to adjuvant 
chemotherapy32,62. The randomly considered study attrition rate was acceptable for both groups. In addition to 
the level of physical inactivity identified, we observed several physiological and biological indicators of meta-
bolic syndrome that were raised among 42% of the recruited population, constituting an elevated risk profile. 
At baseline, 23 patients (15%) were medically treated for a cardiovascular risk component and were moderately 
Panel A:
Group
T0 (n = 
153)
T1 (n = 
125)
T2 (n = 
126)
T3 (n = 
117)
(95% CI) p Value
Diff. p
HADS Mean (SD) Mean (SD) Mean (SD) Mean (SD) (95% CI) Value
HADS Anxiety 1 4.4 (4.0) 4.4 (3.9) 1.0 (0.4 to 1.7) 0.002 0.9 (0.0 to 1.8) 0.0591
(Scale 0–21)
2 5.2 (3.8) 4.8 (3.9) 0.2 (−0.5 to 0.8) 0.6483
1 4.4 (4) 4.0 (3.7) 1.3 (0.5 to 2.1) 0.0017 −0.3 (−1.4 to 0.8) 0.6251
2 5.2 (3.9) 5.3 (3.9) 1.5 (0.8 to 2.3) 0.0001
1 4.3 (4.0) 3.9 (3.7) −0.8 (−1.5 to −0.1) 0.0304 −0.3 (−1.4 to 0.7) 0.5193
2 5.0 (3.8) 4.8 (4.0) −0.5 (−1.2 to 0.3) 0.2108
HADS Depression 1 3.3 (2.8) 4.3 (3.3) 1.0 (0.4 to 1.7) 0.002 0.9 (0 to 1.8) 0.0591
(Scale 0–21)
2 3.7 (3.5) 4.0 (3.7) 0.2 (−0.5 to 0.8) 0.6483
1 3.3 (2.8) 4.6 (3.4) 1.3 (0.5 to 2.1) 0.0017 −0.3 (−1.4 to 0.8) 0.6251
2 3.7 (3.4) 5.4 (4.0) 1.5 (0.8 to 2.3) 0.0001
1 3.2 (2.8) 2.5 (2.7) −0.8 (−1.5 to −0.1) 0.0304 −0.3 (−1.4 to 0.7) 0.5193
2 3.4 (3.2) 3.1 (3.1) −0.5 (−1.2 to 0.3) 0.2108
Panel B: Selected EORTC scales
EORTC Global Health Status 1 60 (21) 52 (24) −8 (−14 to −3) 0.0021 −6 (−14 to 1) 0.1125
(Scale 0–100) 2 60 (21) 58 (23) −2 (−8 to 3) 0.3780
1 61 (21) 56 (22) −4 (−10 to 2) 0.1905 6 (−2 to 15) 0.1288
2 62 (22) 51 (20) −11 (−16 to −5) 0.0005
1 62 (21) 76 (19) 15 (9 to 21) <0.0001 8 (0 to 16) 0.0517
2 63 (21) 69 (23) 7 (1 to 13) 0.0208
EORTC Fatigue 1 42 (25) 52 (26) 10 (3 to 17) 0.0036 8 (−2 to 18) 0.0977
(Scale 0–100) 2 49 (25) 50 (26) 2 (−5 to 9) 0.5333
1 42 (25) 58 (27) 17 (9 to 25) <0.0001 5 (−6 to 16) 0.3491
2 48 (25) 59 (25) 12 (4 to 19) 0.0033
1 40 (25) 29 (24) −12 (−18 to −5) 0.0005 −4 (−13 to 6) 0.4300
2 46 (24) 38 (26) −8 (−15 to −1) 0.0168
1 17 (21) 31 (32) 15 (7 to 24) 0.0004 9 (−3 to 21) 0.1357
EORTC Pain 2 22 (26) 29 (31) 6 (−2 to 15) 0.1236
(Scale 0–100)
1 18 (21) 32 (30) 16 (8 to 24) <0.0001 −3 (−14 to 8) 0.6209
2 22 (26) 42 (29) 19 (11 to 27) <0.0001
1 17 (20) 22 (22) 6 (−1 to 12) 0.0778 6 (−3 to 15) 0.1973
2 20 (24) 21 (23) 0 (−7 to 6) 0.9464
1 10 (22) 20 (23) 11 (4 to 17) 0.0026 4 (−5 to 14) 0.3656
EORTC Dyspnoea 2 13 (22) 19 (27) 6 (−1 to 13) 0.0707
(Scale 0–100)
1 10 (22) 28 (31) 18 (9 to 27) 0.0001 2 (−11 to 14) 0.7901
2 12 (22) 30 (31) 16 (8 to 25) 0.0003
1 10 (22) 10 (19) 0 (−7 to 7) 0.9566 0 (−10 to 9) 0.9885
2 8 (17) 12 (22) 0 (−6 to 7) 0.9407
Table 5. Selected patient-reported outcomes. Abbreviations: *=between-group difference; TO = baseline; 
T1 = week 6, midway; T2 = week 12, completed; T3 = week 39, follow-up; 1 = group 1 supervised exercise 
intervention; 2 = group 2 pedometer exercise intervention; SD = standard deviation; CI = confidence interval; 
EORTC = European Organisation for Research and Treatment of Cancer − Quality of Life Questionnaire; 
HADS = Hospital Anxiety Depression Scale.
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overweight, with an average body mass index >26 (SD 5.15]. Several studies have observed weight gain follow-
ing BC treatment associated with an increased metabolic long-term risk63–65. Metabolic syndrome may increase 
BC recurrence three-fold and BC-specific mortality approximately two-fold66. CRF and muscle strength have 
been shown to have an inversely independent association on metabolic cardiovascular risk factors in adults67. 
Likewise, moderate to vigorous leisure time PA is inversely associated with metabolic syndrome68. Thus, the 
improved metabolic risk profile and stable weight development achieved in the present study validate the cohe-
sion of physiological and patient-reported PA outcomes, suggesting the treatment complementary effectiveness 
of the interventions to improve important clinical risk outcomes. We believe this transverse cohesion, along with 
the systematic recruitment of physically inactive BC patients, constitutes the primary clinical importance in the 
approach and findings of this trial.
In line with several RCTs and metanalysis evaluating combined cardio and resistance exercise interven-
tions31,32,69,70, our findings indicate a significant positive effect on physical functioning in the supervised exercise 
group, with an effect size considered subjectively meaningful71. Similarly, in agreement with previous studies 
evaluating the effect of resistance exercise19,23,31,32,72, we found that participation in the supervised exercise inter-
vention maintained or improved muscle strength in the lower and upper extremities, with one repetition maxi-
mum strength increases corresponding to 20% and 22% (knee extension and leg press, respectively) and 17% in 
the lateral pull exercise post-intervention. Muscle strength after chemotherapy for BC survivors without inter-
vention has been found to be 12–16% lower in the upper extremities, and 25% lower in the lower extremities, 
compared to healthy women72. This is of potential clinical importance as declines in muscle strength have been 
associated with loss of function in BC survivors, affecting the ability to perform recreational and daily living 
activities73. Considering the relationship between muscle strength and sarcopenia, our findings have potential 
Figure 6. Global overview of effect sizes.
Panel A: Correlation Δ Fatigue Δ Pain Δ Dyspnoea
Δ Contrex right −0.12 (−0.29, 0.06) −0.01 (−0.19, 0.16) 0.04 (−0.14, 0.22)
Δ Contrex left −0.04 (−0.22, 0.13) −0.03 (−0.21, 0.14) −0.04 (−0.22, 0.13)
Δ Lean mass −0.18 (−0.34, 0.00) −0.11 (−0.28, 0.07) −0.04 (−0.21, 0.14)
Δ Leg press −0.07 (−0.25, 0.11) −0.22 (−0.38, −0.04) −0.12 (−0.29, 0.07)
Δ VO2peak −0.31 (−0.46, −0.14) −0.25 (−0.41, −0.08) −0.27 (−0.42, −0.09)
Panel B: Parametric
Δ Contrex right (5 N m) −1.3 (−3.3, 0.7) −0.1 (−2.1, 1.8) 0.5 (−1.7, 2.7)
Δ Contrex left (5 N m) −0.5 (−2.4, 1.4) −0.4 (−2.3, 1.5) −0.5 (−2.6, 1.6)
Δ Lean Mass (0.5 kg) −1.4 (−2.8, 0.0) −0.8 (−2.3, 0.6) −0.3 (−2.0, 1.3)
Δ Leg press (10 kg) −0.8 (−3.2, 1.7) −2.7 (−5.2, −0.3) −1.8 (−4.5, 1.0)
Δ VO2peak (100 ml) −4.0 (−6.1, −1.8) −3.2 (−5.4, −1.1) −3.7 (−6.1, −1.3)
Table 6. Correlations and parametric values between delta physiological outcomes and delta selected patient-
reported outcome scales.
1 2Scientific RepoRtS |         (2020) 10:9710  | https://doi.org/10.1038/s41598-020-66513-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
clinical implications as BC sarcopenia, even early stage, has been associated with poorer survival and shorter 
time to tumour progression74. Our results indicate that exercise during adjuvant chemotherapy, with super-
vised heavy-load resistance training, provides the strongest effects and may ameliorate the detrimental effects of 
chemotherapy on skeletal muscles72,74,75, irrespective of cardiorespiratory deterioration.
EORTC patient-reported outcomes showed an increasing symptom profile on, e.g. fatigue, pain, dyspnoea and 
insomnia during the intervention period and without any in-between group differences. However, the explorative 
analyses showed that, across groups, the individuals who were able to maintain or improve CRF (33%) showed sig-
nificant improvement on several EORTC QLQ scales. The correlation analyses between physiological outcomes and 
patient-reported outcomes suggested that CRF is inversely correlated with reduced fatigue, pain and dyspnoea, while 
muscle indicators had almost no correlation. This finding is in line with the study’s rationale and overall assump-
tions38. These results support the notion that pathways and interplay between physiological measures and patient 
perceived benefits on symptomatology and side effects are complex and far from being understood31.
The two present interventions were designed to appeal to and motivate BC patients who did not meet the 
Danish national PA guidelines and were concurrently referred to adjuvant chemotherapy. The findings showed 
that interventions were equally effective with respect to supporting behavioural changes towards adopting an 
adequate transition to PA in everyday life activities for several participants, during and post chemotherapy. It 
has been suggested that health professional counselling rooted in cognitive behavioural therapy and possessing 
a central basis in PA interventions has a positive effect on maintaining PA adherence rate for patients with can-
cer76. Two studies preceding the present RCT indicated that recommendations from the oncologist, the screening 
procedure, the objective physiological tests and the counselling sessions with the clinical nurse specialist were 
crucial to patient recruitment, adherence and patients feeling safe when initiating PA during their treatment 
cycles27,36. The recurring counselling sessions were carried out face to face between the clinical nurse specialist 
and patients. Besides serving as motivation, these sessions, by incorporating social cognitive theory77 and behav-
ioural change strategies36,78, targeted exercise intolerance by taking into account the individual patient’s symptom 
profile, reducing side effect-related dropout and by addressing the habits and structural barriers in daily living. 
Accordingly, we suggest that interventions should be integrated into a treatment context that aligns with patient 
needs and preferences in terms of becoming physically active during adjuvant chemotherapy36. Consequently, 
exercise oncology ideology based primarily on physiological mechanisms and exercise prescriptions79 may poten-
tially underestimate the role the human dynamic plays, as well as the environmental impact on motivation and 
PA sustainability36.
One of the strengths in the present study is the focus on a longitudinal clinical profile in PA screened survivors 
with breast cancer by using gold standard measures on various physiological outcomes with a low risk of bias. The 
clinicians who pre-screened for physical inactivity present at adjuvant chemotherapy secured recruitment of the 
targeted population at risk, underpinning the validity and reliability of the two-item screening tool. A potential 
selection bias relates to the fact that patients were likely to be more highly educated. This is consistent, on the one 
hand, with the inverse social gradient in BC populations80,81, but could indicate, on the other, selection of the most 
highly motivated among the less active. It is a weakness that we did not incorporate a non-intervention control 
group, but this was not possible for ethical reasons associated with standard hospital exercise programmes19. The 
15% dropout rate at T2 may have caused a selection bias, though we did not identify explanatory variables signif-
icantly associated with the attrition.
conclusions
In conclusion, our study shows that beneficial effects can be obtained from supervised intensive, hospital-based 
exercise programmes but also from a less demanding pedometer exercise intervention under guidance and coun-
selling from committed health professionals. Both interventions were effective in supporting formerly inactive BC 
patients in sustaining PA activities during and following adjuvant treatment. Restored CRF at follow-up and met-
abolic indicators showed an improved health profile and subsequently a decline in cardiovascular risk. Clinicians 
should address patient-specific modifiable risks within a medical and preventative scope, especially to support 
motivational progress and to counteract cumbersome barriers, such as treatment-related toxicity, factors that 
constantly challenge motivation and exercise intolerance in physically inactive BC survivors.
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